Vergelijking

Pemvidutide vs. Petrelintide

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Metabool

CAS-nr.

geen gegevens

Molecuulmassa

geen gegevens

Halfwaardetijd

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Pemvidutide

The GLP-1 component suppresses appetite while the glucagon component raises energy expenditure and acts directly on hepatic fat metabolism — the combination is intended to mimic the complementary effects of diet and exercise.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Bewijsbasis

Hoogste bewijs

Humane studie

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Pemvidutide	Petrelintide
Duitsland	Niet goedgekeurd	Niet goedgekeurd
Verenigde Staten	Niet goedgekeurd	Niet goedgekeurd

Volledige vermeldingen

Pemvidutide

Volledige vermelding →

Petrelintide

Volledige vermelding →

Frequently asked questions

What is the difference between Pemvidutide and Petrelintide?: Pemvidutide is classified as "Metabool", while Petrelintide is classified as "Metabool". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pemvidutide or Petrelintide?: The highest available evidence level is "Humane studie" for Pemvidutide and "Humane RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pemvidutide and Petrelintide in Germany and the United States?: Duitsland: Pemvidutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. Verenigde Staten: Pemvidutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.

Country

Pemvidutide

Petrelintide

Duitsland

Niet goedgekeurd

Verenigde Staten

Niet goedgekeurd

Frequently asked questions

What is the difference between Pemvidutide and Petrelintide?

Pemvidutide is classified as "Metabool", while Petrelintide is classified as "Metabool". Pemvidutide: Pemvidutide is a 29-amino-acid GLP-1/glucagon dual receptor agonist (Altimmune) under investigation for obesity and the fatty-liver disease MASH. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pemvidutide or Petrelintide?

The highest available evidence level is "Humane studie" for Pemvidutide and "Humane RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pemvidutide and Petrelintide in Germany and the United States?

Duitsland: Pemvidutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. Verenigde Staten: Pemvidutide — Niet goedgekeurd, Petrelintide — Niet goedgekeurd. These are factual summaries with source and review date on the individual pages.